Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

Cancer Cell

Volumn 22, Issue 5, 2012, Pages 668-682

  Lito, Piro ^a   Pratilas, Christine A ^a   Joseph, Eric W ^a   Tadi, Madhavi ^a   Halilovic, Ensar ^b   Zubrowski, Matthew ^b   Huang, Alan ^b   Wong, Wai Lin ^a   Callahan, Margaret K ^a   Merghoub, Taha ^a   Wolchok, Jedd D ^a   de Stanchina, Elisa ^a   Chandarlapaty, Sarat ^a   Poulikakos, Poulikos I ^a   Fagin, James A ^a   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF V600E PROTEIN; DABRAFENIB; DIMER; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MONOMER; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NERATINIB; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAF PROTEIN INHIBITOR; RAS PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; ENZYME ACTIVITY; MELANOMA; MITOGENESIS; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STEADY STATE;

EID: 84869067183     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.10.009     Document Type: Article

References (44)

1. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
2. Badalian-Very G., Vergilio J.A., Degar B.A., MacConaill L.E., Brandner B., Calicchio M.L., Kuo F.C., Ligon A.H., Stevenson K.E., Kehoe S.M., et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010, 116:1919-1923.
3. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
4. Basso A.D., Solit D.B., Chiosis G., Giri B., Tsichlis P., Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 2002, 277:39858-39866.
5. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
6. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62:6997-7000.
7. Chapman P.B., Hauschild A., Robert C., Haanen J.B., Ascierto P., Larkin J., Dummer R., Garbe C., Testori A., Maio M., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516. BRIM-3 Study Group.
8. Corcoran R.B., Ebi H., Turke A.B., Coffee E.M., Nishino M., Cogdill A.P., Brown R.D., Della Pelle P., Dias-Santagata D., Hung K.E., et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012, 2:227-235.
9. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
10. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
11. Dougherty M.K., Müller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 2005, 17:215-224.
12. Douville E., Downward J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene 1997, 15:373-383.
13. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
14. Eblaghie M.C., Lunn J.S., Dickinson R.J., Münsterberg A.E., Sanz-Ezquerro J.J., Farrell E.R., Mathers J., Keyse S.M., Storey K., Tickle C. Negative feedback regulation of FGF signaling levels by Pyst1/MKP3 in chick embryos. Curr. Biol. 2003, 13:1009-1018.
15. Hanafusa H., Torii S., Yasunaga T., Nishida E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 2002, 4:850-858.
16. Harbinski F., Craig V.J., Sanghavi S., Jeffery D., Liu L., Sheppard K.A., Wagner S., Stamm C., Buness A., Chatenay-Rivauday C., et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2012, 2:948-959.
17. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
18. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
19. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003, 63:5198-5202.
20. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
21. Kim H.J., Bar-Sagi D. Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell Biol. 2004, 5:441-450.
22. Kirkwood J.M., Bastholt L., Robert C., Sosman J., Larkin J., Hersey P., Middleton M., Cantarini M., Zazulina V., Kemsley K., Dummer R. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 2012, 18:555-567.
23. Leboeuf R., Baumgartner J.E., Benezra M., Malaguarnera R., Solit D., Pratilas C.A., Rosen N., Knauf J.A., Fagin J.A. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 2008, 93:2194-2201.
24. Mason J.M., Morrison D.J., Basson M.A., Licht J.D. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol. 2006, 16:45-54.
25. McCormick F. Signal transduction. How receptors turn Ras on. Nature 1993, 363:15-16.
26. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
27. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
28. Nimnual A., Bar-Sagi D. The two hats of SOS. Sci. STKE 2002, 2002:pe36.
29. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
30. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
31. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
32. Pratilas C.A., Hanrahan A.J., Halilovic E., Persaud Y., Soh J., Chitale D., Shigematsu H., Yamamoto H., Sawai A., Janakiraman M., et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 2008, 68:9375-9383.
33. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
34. Schiffman J.D., Hodgson J.G., VandenBerg S.R., Flaherty P., Polley M.Y., Yu M., Fisher P.G., Rowitch D.H., Ford J.M., Berger M.S., et al. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res. 2010, 70:512-519.
35. Sebolt-Leopold J.S., Dudley D.T., Herrera R., Van Becelaere K., Wiland A., Gowan R.C., Tecle H., Barrett S.D., Bridges A., Przybranowski S., et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. 1999, 5:810-816.
36. Solit D.B., Rosen N. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 2011, 364:772-774.
37. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
38. Sosman J.A., Kim K.B., Schuchter L., Gonzalez R., Pavlick A.C., Weber J.S., McArthur G.A., Hutson T.E., Moschos S.J., Flaherty K.T., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 2012, 366:707-714.
39. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
40. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., Pucciarini A., Bigerna B., Pacini R., Wells V.A., et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 2011, 364:2305-2315.
41. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 2008, 105:3041-3046.
42. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5:875-885.
43. Wellbrock C., Ogilvie L., Hedley D., Karasarides M., Martin J., Niculescu-Duvaz D., Springer C.J., Marais R. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004, 64:2338-2342.
44. Wilson T.R., Fridlyand J., Yan Y., Penuel E., Burton L., Chan E., Peng J., Lin E., Wang Y., Sosman J., et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487:505-509.